Condition: Blood Platelet Disorder · BRAF V600E · Thyroid Nodule · Sponsor: Saglik Bilimleri Universitesi
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology. The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology. Primary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.
This description comes directly from the study's public registry record.
Ugur 1 Kesici, Assoc. Prof. · 00905445474710 · ugur.kesici@sbu.edu.tr
Ugur 1 Kesici, Assoc. Prof. · 00905445474710 · ugurkesici77@mynet.com
Always discuss trial participation with your own doctor first.
| Prof. Dr. Cemil Tascioglu City Hospital | Istanbul, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06539702